Howard Jacob, Ph.D., vice president of genomics research and head of data convergence: Convergence is in some sense exactly what it sounds like — it’s bringing together different types of data to create knowledge. We have access to so much data here at AbbVie: preclinical and clinical trial data, public databases, data from scientific publications, and a million genomes — that’s a lot of data!
So, data convergence was born out of the question “how do we take all of that information and put it together so that we can drive new knowledge much faster?”
What are the data science skills needed to unlock new knowledge?
Jennifer Van Camp, Ph.D., senior director and research fellow, R&D, information research: There are a lot of disciplines that are represented on data science teams at AbbVie that one doesn't necessarily think of as typical for the pharmaceutical industry. We have electrical engineers with experience in signal and image processing, computational linguists, data engineers, and life scientists like me on our data science teams. It’s the mix of different core strengths and experiences that make progress possible.
What are some data science tools AbbVie is building to bridge the gap from data to knowledge and insights?
Jacob: We’ve built a central knowledge platform called the ARCH, which stands for AbbVie R&D Convergence Hub. It pulls together all these different data sets into one place. It incorporates different types of information tools that allow us to ask new questions and gain additional insights. With ARCH, we’re able to learn new things about disease definitions, discover new indications, and take a deeper look into understanding the molecular underprint of a disease. In a sense, it democratizes the data.
Brian Martin, head of artificial intelligence & search fellow, R&D, information research: The powerful thing about the ARCH is that it’s a knowledge platform versus a data platform. What makes it that way is our scientists and having them explain what makes a specific piece of data information meaningful.
Can data convergence help us identify potential new treatments for unmet patient needs?
Martin: The real-world data we have access to provides us with the opportunity to ask ourselves questions regarding patients’ experiences to quantify their unmet needs from various perspectives. For example, we can now look at preclinical data alongside clinical data and data from insurance claims. This can help us connect the various impacts that a certain compound might have on patients. That ability to bridge the gap from the real-world data back to preclinical data in the lab, that's the power of integration to affect the way we bring assets into our pipeline.
Any advice for someone interested in a career in data convergence?
Van Camp: I don’t think there is a single answer – there’s not one class you should take or a degree you need. But I always believe in being relentlessly curious. As an organization, industry, and a society, we have to keep asking those hard questions that we can't answer.
Watch AbbVie’s recent LinkedIn Live event: “What’s the Formula? Tackling the digital health revolution” for more from AbbVie’s data convergence leaders.